PubRank

ADPKD Alterations in Hepatic Transporter Function

Clinical Trial ID NCT03717883

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03717883

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002 3.52
2 The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 2000 2.31
3 Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004 2.20
4 Properties of internal pilots with the univariate approach to repeated measures. Stat Med 2003 1.63
5 Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003 1.41
6 Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis 2014 1.35
7 Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2). Eur J Hum Genet 2004 1.26
8 Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf 2015 1.02
9 Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci 2015 0.92
10 Sample size recalculation using conditional power. Stat Med 2001 0.90
11 Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol 2015 0.84
12 Internal pilots for observational studies. Biom J 2010 0.83
13 Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. J Pharmacol Exp Ther 2016 0.77
14 Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species. J Pharmacol Exp Ther 2016 0.76
15 Liver cysts associated with polycystic kidney disease: role of Tc-99m hepatobiliary imaging. Clin Nucl Med 1989 0.75
16 Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay. Drug Metab Dispos 2017 0.75
17 Adaptive sample size modification in clinical trials: start small then ask for more? Stat Med 2015 0.75
18 Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol 2016 0.75
Next 100